Last reviewed · How we verify

Third generation cephalosporins — Competitive Intelligence Brief

Third generation cephalosporins (Third generation cephalosporins) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (cephalosporin). Area: Infectious Disease.

marketed Beta-lactam antibiotic (cephalosporin) Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Third generation cephalosporins (Third generation cephalosporins) — Wyeth is now a wholly owned subsidiary of Pfizer. Third-generation cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Third generation cephalosporins TARGET Third generation cephalosporins Wyeth is now a wholly owned subsidiary of Pfizer marketed Beta-lactam antibiotic (cephalosporin) Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (cephalosporin) class)

  1. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Third generation cephalosporins — Competitive Intelligence Brief. https://druglandscape.com/ci/third-generation-cephalosporins. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: